Prescribing Context
LDX prodrug mechanism, HAP abuse liability data, step therapy evidence, and managed care rationale.
LDX Prodrug Mechanism
Lisdexamfetamine (Vyvanse) is pharmacologically inactive until converted in the bloodstream by red blood cell enzymatic hydrolysis into active d-amphetamine.
| Property | Evidence |
|---|---|
| Cannot be abused by snorting/injecting | Molecular proof LDX is inactive until blood conversion (2013) |
| 13–14 hour duration of action | Unique blood-based enzymatic conversion (2016) |
| Consistent across populations | Stable PK across ethnic and metabolic groups (2020) |
| Food/pH independent | Gastric pH and food intake do not alter absorption (2012) |
| Onset within 1.5h, duration up to 13h | Wigal SB, et al. — Clin Ther (2010) |
HAP Study — Human Abuse Potential Data
The Human Abuse Potential (HAP) study is the FDA gold standard. Subjects are experienced stimulant users — required by FDA protocol to establish the theoretical maximum abuse signal. These findings apply to extraordinary conditions, not ordinary therapeutic populations.
| Drug | Schedule | Role | Reinforcing Strength |
|---|---|---|---|
| LDX (Vyvanse) | CII | Test Compound | Attenuated at therapeutic dose; converges at supratherapeutic |
| D-Amphetamine IR | CII | Positive Control | Baseline high liability |
| Methamphetamine | CII | Indirect Comparator | Greater than D-Amphetamine |
| Cocaine | CII | Indirect Comparator | Equal or greater than D-Amphetamine |
| Diethylpropion | CIV | Low-liability Benchmark | Lower liking score |
Key HAP findings:
- 100 mg LDX (therapeutic): Drug-liking scores not statistically different from diethylpropion (Schedule IV) — significantly lower than D-amphetamine 40 mg
- 150 mg LDX (supratherapeutic): Scores converge with D-amphetamine 40 mg — this ceiling defines scheduling and REMS boundaries
- Real-world diversion: Health Canada (2018) documents reduced diversion rates for LDX vs. IR amphetamine
Untreated ADHD Risk
The clinical risk of not treating ADHD must be weighed against any prescribing concerns. Formulary barriers that delay or deny treatment carry their own documented risk profile.
| Finding | Citation |
|---|---|
| Untreated ADHD linked to 2× higher mortality from accidents | Dalsgaard S, et al. — The Lancet (2015) |
| 208 reports proving untreated ADHD causes higher mortality and long-term morbidity | Clinical Guideline (2021) |
| Active treatment reduces incidence of secondary mood disorders | Caye A, et al. — Mol Psychiatry (2019) |
| Treatment mitigates workplace impairment and workforce loss | de Graaf R, et al. (2008) |
| Effective treatment reduces workplace liability and ER visits | Clinical Guideline (2013) |
Step Therapy Evidence
| Issue | Evidence |
|---|---|
| Step therapy increases total costs | Restrictive insurance policies increase total costs (2015) |
| Generics are not equivalent | Different release curves produce different clinical outcomes (2019) |
| Adherence advantage for LDX | Patients stay on Vyvanse significantly longer than generic salts (2019) |
| Individualized dosing is medically necessary | Against "cookie-cutter" dosing; justifies medical necessity for dose variation (2015) |
| Switching class is standard protocol | If one stimulant class fails, the other must be tried (2007) |
National Guideline Consensus
| Organization | Country | Guideline Position |
|---|---|---|
| NICE (NG87) | UK | Long-acting stimulants as first-line adult treatment (2018) |
| CADDRA | Canada | LDX first-line due to consistent delivery (2020–2024) |
| AADPA | Australia | LDX formalized as first-line for adults (2022) |
| DGPPN (S3) | Germany | Stimulants improve symptoms without addiction risk (2024) |
| Cochrane Review | International | Stimulants reduce hyperactivity — meta-analysis (2025) |
| Epistemonikos | International | Efficacy increases with higher stimulant dosing (2024) |